BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 273,761 shares of the biotechnology company's stock after buying an additional 7,094 shares during the period. California State Teachers Retirement System owned 0.14% of BioMarin Pharmaceutical worth $17,994,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BMRN. Swedbank AB lifted its holdings in BioMarin Pharmaceutical by 11.2% in the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock valued at $28,403,000 after acquiring an additional 43,593 shares during the last quarter. Vestal Point Capital LP increased its holdings in BioMarin Pharmaceutical by 115.0% in the fourth quarter. Vestal Point Capital LP now owns 860,000 shares of the biotechnology company's stock valued at $56,528,000 after buying an additional 460,000 shares during the last quarter. Rhumbline Advisers increased its holdings in BioMarin Pharmaceutical by 2.0% in the fourth quarter. Rhumbline Advisers now owns 556,255 shares of the biotechnology company's stock valued at $36,563,000 after buying an additional 11,025 shares during the last quarter. Mediolanum International Funds Ltd purchased a new position in BioMarin Pharmaceutical in the fourth quarter valued at $1,237,000. Finally, Empowered Funds LLC purchased a new position in BioMarin Pharmaceutical in the fourth quarter valued at $257,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Trading Up 0.3%

NASDAQ BMRN traded up $0.19 during mid-day trading on Tuesday, reaching $57.24. 551,928 shares of the stock were exchanged, compared to its average volume of 1,869,319. The stock has a market capitalization of $10.98 billion, a PE ratio of 26.02, a PEG ratio of 0.61 and a beta of 0.27. The business's fifty day simple moving average is $60.79 and its 200 day simple moving average is $64.44. BioMarin Pharmaceutical Inc. has a 1-year low of $52.93 and a 1-year high of $94.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BMRN shares. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price for the company in a research note on Monday, February 24th. Cantor Fitzgerald restated an "overweight" rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Scotiabank raised their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a research report on Thursday, February 20th. Citigroup reduced their price objective on shares of BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Finally, UBS Group raised their price objective on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $93.45.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now owns 16,955 shares in the company, valued at $1,212,621.60. This trade represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 3,354 shares of company stock worth $216,269 in the last quarter. 0.85% of the stock is owned by insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.